Matinas BioPharma to Present at 29th Annual ROTH Conference

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
40
Matinas BioPharma to Present at 29th Annual ROTH Conference

BEDMINSTER, N.J., March 10, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that Jerome D. Jabbour, Co-Founder and President , will present at the 29 th Annual ROTH Conference on Wednesday, March 15, 2017 at 11:00 a.m. PT in Dana Point, CA.

As part of his presentation, Mr. Jabbour will provide an update on Matinas BioPharma’s recent corporate advancements as well as discuss the Company’s Phase 2 clinical program of its lead antifungal product candidate, MAT2203 , an orally administered, lipid-crystal nano-particle formulation of broad spectrum fungicidal agent amphotericin B, and its plans to advance into a pivotal, registration program.

Mr. Jabbour will also discuss the Company’s Phase 1 clinical program of MAT2501 , an orally-administered, encochleated formulation of the broad spectrum aminoglycoside antibiotic agent amikacin for acute bacterial infections, including non-tuberculous mycobacteria (NTM) and multidrug-resistant gram negative bacterial infections.

A live audio webcast of the presentation will be available on the Events page of the Investors section of the Company’s website ( www.matinasbiopharma.com ). A webcast replay will be accessible for 90 days following the live presentation.

About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead drug candidate MAT2203, currently in Phase 2, is an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent). The Company has an open Investigational New Drug (IND) application for MAT2501, currently in Phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections.

The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology. For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter , LinkedIn , Facebook , and Google+ .

Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's strategic focus and the future development of its product candidates, including MAT2203 and MAT2501, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to maintain and derive benefit from the Qualified Infectious Disease Product (QIDP), Orphan and/or Fast Track designations for MAT2203 and MAT2501, which does not change the standards for regulatory approval or guarantee regulatory approval on an expedited basis, or at all; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

Investor Contact Jenene Thomas Jenene Thomas Communications, LLC Phone: +1 (908) 938-1475 Email: jenene@jenenethomascommunications.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 75

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 142

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 141

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
SANY's Bold AI Showdown at bauma CHINA 2026

Updated Category News Views 27

SANY's Future Vision: AI Agents and Robotic Machinery The construction machinery game is about to get a whole lot smarter, if SANY has anything to say about it. They're rolling out their biggest show ever at bauma CHINA 2026, and the headline act? A fresh breed of AI agents and robotic machinery that promises to revolutionize the industry. Marking its 40-year legacy, SANY...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 89

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
iHeartMedia Faces 65% Drop: Fraud Investigation Launched

Updated Category News Views 62

Trouble Tunes for iHeartMedia Investors Alright folks, here's the skinny on iHeartMedia, Inc. These days, it's like everyone's out for a piece of iHeart, and not in the way you'd wanna see—unless you're SBS Law, those shareholder rights hotshots diving into another pond of legal ripples. Seems a heap of head-scratching's going down on their version of transparency with...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 301

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 128

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 104

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
d -->

Top 5 Most Recently Viewed Articles

Market Fluctuations: NVIDIA, Micron, and SMCI Stocks Overview

Updated Category News Views 192

Market Update for NVIDIA, Micron, and SMCI Stocks Shares of NVIDIA Corp. (NASDAQ: NVDA), Super Micro Computer, Inc. (NASDAQ: SMCI), and Micron Technology, Inc. (NASDAQ: MU) have recently taken a noticeable dip. This drop has caught the eye of both investors and market analysts, leading to questions about what might be driving this trend. Current Hurdles in the...

Continue Reading
Hyundai Motor Shines at Cannes with Grand Prix and Gold Lions

Updated Category News Views 250

Hyundai Motor's Exceptional Recognition at Cannes Lions Hyundai Motor Company has made a remarkable impact at the prestigious Cannes Lions International Festival of Creativity. The company has achieved a Grand Prix award for its short film, 'Night Fishing,' a project that has been praised for its inventive storytelling and creative prowess. This Grand Prix marks a...

Continue Reading
EWTN's Expansion in Stockholm: A Strategic Faith Move

Updated Category News Views 54

A Bold Move into Northern Europe In what's shaping up to be a calculated leap of faith, the EWTN Global Catholic Network opened a new office in Stockholm, Sweden. Now, I don't usually get all warm and fuzzy over religious broadcasts, but this is less about spreading sermons and more about tapping into a growing market. Yeah, you heard me right—market. With the Catholic...

Continue Reading
Investors Urged to Act Now Amid 143% Cash Flow Decline

Updated Category News Views 135

Significant Concerns for StubHub Investors Investors in StubHub Holdings, Inc. (NYSE: STUB) are being urged to pay close attention as serious allegations surface concerning the company's recent financial disclosures. The prominent investor rights law firm Hagens Berman is reaching out to those investors who acquired shares during the company's Initial Public Offering...

Continue Reading
Walmart Leverages Automation to Rival Amazon's Dominance

Updated Category News Views 200

Walmart Ignites Technological Transformation Walmart Inc (NYSE: WMT) is not just a retailer; it's transforming into a technology powerhouse. While many might think of Amazon.com Inc (NASDAQ: AMZN) as the leader in tech-driven logistics, Walmart is ramping up its efforts. Recently, during a call with investors, the company's CFO highlighted a key milestone: "More than 50%...

Continue Reading